Biomarkers in cancer immunotherapy

Antibodies against T cell checkpoint molecules have started to revolutionize cancer treatment. Nevertheless, less than half of all patients respond to these immunotherapies. Recent work supports the potential value of biomarkers that predict therapy outcome and inspires the development of assay syst...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer cell Ročník 27; číslo 1; s. 12
Hlavní autoři: Schumacher, Ton N, Kesmir, Can, van Buuren, Marit M
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 12.01.2015
Témata:
Antibodies, Neoplasm - therapeutic use
Biomarkers, Tumor - genetics
Biomarkers, Tumor - immunology
Humans
Immunotherapy - methods
Neoplasms - genetics
Neoplasms - immunology
T-Lymphocytes - immunology
ISSN:1878-3686, 1878-3686
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Antibodies against T cell checkpoint molecules have started to revolutionize cancer treatment. Nevertheless, less than half of all patients respond to these immunotherapies. Recent work supports the potential value of biomarkers that predict therapy outcome and inspires the development of assay systems that interrogate other aspects of the cancer-immunity cycle.
AbstractList Antibodies against T cell checkpoint molecules have started to revolutionize cancer treatment. Nevertheless, less than half of all patients respond to these immunotherapies. Recent work supports the potential value of biomarkers that predict therapy outcome and inspires the development of assay systems that interrogate other aspects of the cancer-immunity cycle.
Antibodies against T cell checkpoint molecules have started to revolutionize cancer treatment. Nevertheless, less than half of all patients respond to these immunotherapies. Recent work supports the potential value of biomarkers that predict therapy outcome and inspires the development of assay systems that interrogate other aspects of the cancer-immunity cycle.Antibodies against T cell checkpoint molecules have started to revolutionize cancer treatment. Nevertheless, less than half of all patients respond to these immunotherapies. Recent work supports the potential value of biomarkers that predict therapy outcome and inspires the development of assay systems that interrogate other aspects of the cancer-immunity cycle.
Author van Buuren, Marit M
Kesmir, Can
Schumacher, Ton N
Author_xml – sequence: 1
  givenname: Ton N
  surname: Schumacher
  fullname: Schumacher, Ton N
  email: t.schumacher@nki.nl
  organization: Division of Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands. Electronic address: t.schumacher@nki.nl
– sequence: 2
  givenname: Can
  surname: Kesmir
  fullname: Kesmir, Can
  organization: Department of Theoretical Biology and Bioinformatics, Utrecht University, 3584 CH Utrecht, the Netherlands
– sequence: 3
  givenname: Marit M
  surname: van Buuren
  fullname: van Buuren, Marit M
  organization: Division of Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25584891$$D View this record in MEDLINE/PubMed
BookMark eNpNj0tLxDAYRYOMOA_9BYIUV25a8-WdpQ6-YMCNrkuapNixTWvSLubfW3EEV_cuzr1w1mgR-uARugRcAAZxuy-s9W1bEAysAFJgzE7QCpRUORVKLP71JVqntMfzCqQ-Q0vCuWJKwwpd3zd9Z-KnjylrQmZNsD5mTddNoR8_fDTD4Ryd1qZN_uKYG_T--PC2fc53r08v27tdbhmVY64tV-Aw89g6qxQXTFpGVF17gimomsiKGY0rq2tZUUIcVFo6p7UjwgJ3ZINufn-H2H9NPo1l16QfQxN8P6USBCdUU6lgRq-O6FR13pVDbGaJQ_nnRb4Bt5NRXg
CitedBy_id crossref_primary_10_3389_fimmu_2021_752042
crossref_primary_10_1186_s13073_019_0679_x
crossref_primary_10_3389_pore_2021_633243
crossref_primary_10_1007_s11912_017_0586_5
crossref_primary_10_1200_EDBK_160766
crossref_primary_10_3389_fmolb_2022_793403
crossref_primary_10_1016_j_ejmech_2023_115465
crossref_primary_10_3390_ijms21197248
crossref_primary_10_1155_2021_6664791
crossref_primary_10_1155_2021_7391560
crossref_primary_10_3389_fphar_2021_720692
crossref_primary_10_1186_s12916_016_0623_5
crossref_primary_10_7554_eLife_07661
crossref_primary_10_1038_mtm_2015_48
crossref_primary_10_1126_science_aad4140
crossref_primary_10_1038_s41392_023_01644_9
crossref_primary_10_3390_cimb47060426
crossref_primary_10_1016_j_imlet_2016_03_007
crossref_primary_10_1111_cas_14113
crossref_primary_10_1002_cam4_6073
crossref_primary_10_1186_s12935_020_01457_8
crossref_primary_10_1158_1078_0432_CCR_20_3054
crossref_primary_10_1002_pmic_201500445
crossref_primary_10_1007_s00262_024_03784_5
crossref_primary_10_3390_vaccines8040776
crossref_primary_10_1016_j_heliyon_2024_e36561
crossref_primary_10_1038_bjc_2016_195
crossref_primary_10_1016_j_critrevonc_2020_103161
crossref_primary_10_1517_14712598_2015_1035251
crossref_primary_10_1080_19420862_2023_2236740
crossref_primary_10_1002_cti2_1111
crossref_primary_10_1002_jgm_3486
crossref_primary_10_1016_j_mayocp_2018_03_028
crossref_primary_10_1093_annonc_mdw165
crossref_primary_10_1016_j_drup_2015_08_003
crossref_primary_10_1093_neuonc_nox026
crossref_primary_10_3389_fgene_2022_850200
crossref_primary_10_1158_1078_0432_CCR_20_1135
crossref_primary_10_3892_ol_2019_9910
crossref_primary_10_1158_0008_5472_CAN_18_1722
crossref_primary_10_3389_fcell_2021_799278
crossref_primary_10_1002_wnan_1855
crossref_primary_10_1016_j_it_2022_03_003
crossref_primary_10_1038_s41467_017_02289_3
crossref_primary_10_1146_annurev_immunol_042617_053402
crossref_primary_10_1016_j_critrevonc_2022_103891
crossref_primary_10_1016_j_biopha_2022_113118
crossref_primary_10_1186_s12885_022_09314_9
crossref_primary_10_3390_cancers13020164
crossref_primary_10_1007_s11912_024_01519_4
crossref_primary_10_1038_s41467_017_00147_w
crossref_primary_10_1016_j_coi_2016_07_005
crossref_primary_10_18632_oncotarget_17397
crossref_primary_10_1007_s12033_022_00580_3
crossref_primary_10_1080_2162402X_2017_1373237
crossref_primary_10_1172_JCI80007
crossref_primary_10_1016_j_str_2015_09_010
crossref_primary_10_1016_j_tcb_2019_01_003
crossref_primary_10_1007_s13346_022_01241_3
crossref_primary_10_1158_1078_0432_CCR_15_1180
crossref_primary_10_1007_s00262_016_1832_7
crossref_primary_10_3389_fnins_2020_603647
crossref_primary_10_1016_j_copbio_2020_05_002
crossref_primary_10_1186_s12964_020_00663_1
crossref_primary_10_3389_fimmu_2022_912594
crossref_primary_10_1002_jcb_28308
crossref_primary_10_1186_s40425_016_0107_3
crossref_primary_10_1186_s13073_016_0333_9
crossref_primary_10_1002_ijc_31878
crossref_primary_10_1186_s12935_020_01273_0
crossref_primary_10_4049_jimmunol_1701099
crossref_primary_10_7554_eLife_53244
crossref_primary_10_3389_fonc_2021_741626
crossref_primary_10_1007_s11307_020_01527_3
crossref_primary_10_1016_j_critrevonc_2018_12_002
crossref_primary_10_1126_science_aad0095
crossref_primary_10_1093_annonc_mdw091
crossref_primary_10_1007_s43538_021_00054_1
crossref_primary_10_1038_nature14395
crossref_primary_10_1186_s13046_023_02653_w
crossref_primary_10_2147_IJGM_S389275
crossref_primary_10_1002_adtp_201900215
crossref_primary_10_1016_j_cplett_2020_138103
crossref_primary_10_3389_fonc_2022_877817
crossref_primary_10_3389_fimmu_2023_1102517
crossref_primary_10_1126_science_aaa4971
crossref_primary_10_1080_17512433_2020_1817737
crossref_primary_10_1126_scitranslmed_aah3560
crossref_primary_10_1186_s12935_024_03305_5
crossref_primary_10_1097_MD_0000000000034861
crossref_primary_10_1186_s12885_021_08356_9
crossref_primary_10_3390_ijms241411233
crossref_primary_10_3389_fimmu_2022_809872
crossref_primary_10_3389_fphar_2022_1030062
crossref_primary_10_1038_s41551_020_00662_0
crossref_primary_10_3389_fonc_2020_564306
crossref_primary_10_3390_ijms232012677
crossref_primary_10_3389_fonc_2017_00190
crossref_primary_10_1093_annonc_mdv382
ContentType Journal Article
Copyright Copyright © 2015 Elsevier Inc. All rights reserved.
Copyright_xml – notice: Copyright © 2015 Elsevier Inc. All rights reserved.
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.ccell.2014.12.004
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1878-3686
ExternalDocumentID 25584891
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
--K
0R~
1~5
29B
2WC
4.4
457
4G.
53G
5GY
62-
6J9
7-5
AACTN
AAEDT
AAEDW
AAKRW
AAKUH
AALRI
AAMRU
AAVLU
AAXUO
ABJNI
ABMAC
ACGFO
ACGFS
ADBBV
ADEZE
ADVLN
AEFWE
AENEX
AEXQZ
AFTJW
AGHFR
AGKMS
AITUG
AKAPO
AKRWK
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ASPBG
AVWKF
AZFZN
BAWUL
CGR
CS3
CUY
CVF
DIK
DU5
E3Z
EBS
ECM
EIF
EJD
F5P
FCP
FDB
FEDTE
FIRID
HVGLF
IH2
IHE
IXB
J1W
JIG
M3Z
M41
NPM
O-L
O9-
OK1
P2P
RIG
ROL
RPZ
SES
SSZ
TR2
UDS
7X8
AAFWJ
AAYWO
ABDGV
ACVFH
ADCNI
AEUPX
AFPUW
AIGII
AKBMS
AKYEP
APXCP
EFKBS
ID FETCH-LOGICAL-c437t-9c581d04e0cdc885647c428ffe20318f27b4a90bc9f7b322d1b97dd99d26c15d2
IEDL.DBID 7X8
ISICitedReferencesCount 125
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000347906900006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1878-3686
IngestDate Sun Sep 28 02:46:47 EDT 2025
Thu Apr 03 07:01:53 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Copyright © 2015 Elsevier Inc. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c437t-9c581d04e0cdc885647c428ffe20318f27b4a90bc9f7b322d1b97dd99d26c15d2
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink http://www.cell.com/article/S1535610814005133/pdf
PMID 25584891
PQID 1652393781
PQPubID 23479
ParticipantIDs proquest_miscellaneous_1652393781
pubmed_primary_25584891
PublicationCentury 2000
PublicationDate 2015-01-12
PublicationDateYYYYMMDD 2015-01-12
PublicationDate_xml – month: 01
  year: 2015
  text: 2015-01-12
  day: 12
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Cancer cell
PublicationTitleAlternate Cancer Cell
PublicationYear 2015
SSID ssj0016179
Score 2.5117118
Snippet Antibodies against T cell checkpoint molecules have started to revolutionize cancer treatment. Nevertheless, less than half of all patients respond to these...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 12
SubjectTerms Antibodies, Neoplasm - therapeutic use
Biomarkers, Tumor - genetics
Biomarkers, Tumor - immunology
Humans
Immunotherapy - methods
Neoplasms - genetics
Neoplasms - immunology
T-Lymphocytes - immunology
Title Biomarkers in cancer immunotherapy
URI https://www.ncbi.nlm.nih.gov/pubmed/25584891
https://www.proquest.com/docview/1652393781
Volume 27
WOSCitedRecordID wos000347906900006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEB7UFfHi-7G-qOI1uEmTJjmJiosHd_GgsLfSPAo92K7bVfDfm2m77EkQzKG3QDOPZDLzZT6Aa-myGAcxXnLCLfNEuZyTWLGc-4GLadvE9VmOx2oy0S9dwq3uYJWLPbHZqF1lMUd-QxOB3bqkorfTD4KsUVhd7Sg0VqEXh1AGrVpOllWEcDpj-EsVQgASlSy6DjX4LouZccR28SYf2DC1_RJjNmfNcPu_f7kDW12UGd21ZrELK77cg41RV0ffh6v7onpHYM6sjooysqj6WVTgW5HuRdb3AbwNH18fnkjHlkAsj-WcaCtC7DkIArbOKiUSLm24W-S5Z-i4OZOGZ3pgrM6lCW7sqNHSOa0dSywVjh3CWlmV_hgiw3yiTeyyLBPcaSTo8caI4Lyx4EyKPlwuVp8Ga0RBZqWvPut0uf4-HLUiTKdt24w0XF4UV5qe_GH2KWwGzSCskFB2Br08-KI_h3X7NS_q2UWj5vAdv4x-ABfmsAI
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Biomarkers+in+cancer+immunotherapy&rft.jtitle=Cancer+cell&rft.au=Schumacher%2C+Ton+N&rft.au=Kesmir%2C+Can&rft.au=van+Buuren%2C+Marit+M&rft.date=2015-01-12&rft.issn=1878-3686&rft.eissn=1878-3686&rft.volume=27&rft.issue=1&rft.spage=12&rft_id=info:doi/10.1016%2Fj.ccell.2014.12.004&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1878-3686&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1878-3686&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1878-3686&client=summon